Please assess the completion status of the following clinical trial:

Trial Title: Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements~* Adult women greater than 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer~  * Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater~ * Hormone receptor positive as defined as ≥ 10% positive stained cells~ * HER2-normal (IHC score 0-1 or FISH negative \[in-situ hybridization (ISH) ratio \<= 2.0 status\])~* Tumor size at least 5 mm with planned primary surgery at Mount Sinai~* A negative urine dipstick pregnancy test~Exclusion Criteria:~* Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells~* Prior antiestrogen therapy~* Tumor size less than 5 mm~* Prior diagnosis of thrombosis or known hypercoagulable state~* Known history of bleeding diathesis~* Known liver disease~* Prior treatment with neoadjuvant therapy~* Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema).~* Current severe or uncontrolled systemic disease~* Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment.~* Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fulvestrant (Type: EXPERIMENTAL): 750 mg injection in 3 divided doses
- Tamoxifen (Type: ACTIVE_COMPARATOR): 20mg orally

Based on this trial design, predict the completion outcome and termination type (if applicable).